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Background: There is increasing interest in hepatocellular carcinomas (HCC) expressing 
“stemness”-related markers, as they have been associated with aggressive behavior and poor 
prognosis. In this study, we investigated the usefulness of Sal-like protein 4 (SALL4), a recently 
proposed candidate marker of “stemness.” Methods: Immunohistochemical stains were per-
formed for SALL4, K19, and epithelial cellular adhesion molecule (EpCAM) on tissue microarrays 
constructed from 190 surgically resected HCCs, and the results were correlated with the clinico-
pathological features and patient survival data. Results: Nuclear SALL4 expression was observed 
in 39/190 HCCs (20.5%), while K19 and EpCAM were expressed in 30 (15.9%) and 92 (48.7%) 
HCCs, respectively. The nuclear expression was generally weak, punctate or clumped. SALL4 ex-
pression was significantly associated with a poor overall survival compared to SALL4-negative 
HCCs (p = .014) compared to SALL4-negative HCCs. On multivariate analysis adjusted for tumor 
size, multiplicity, vascular invasion, and pathological tumor stage, SALL4 remained as a signifi-
cant independent predictor of decreased overall survival (p= .004). SALL4 expression was posi-
tively correlated with EpCAM expression (p = .013) but not with K19 expression. HCCs that ex-
pressed both SALL4 and EpCAM were associated with significantly decreased overall survival, 
compared to those cases which were negative for both of these markers (p = .031). Conclusions: 
Although SALL4 expression was not significantly correlated with other clinicopathological param-
eters suggestive of tumor aggressiveness, SALL4 expression was an independent predictor of 
poor overall survival in human HCCs, and was also positively correlated with EpCAM expression.
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▒ ORIGINAL ARTICLE ▒
Hepatocellular carcinoma (HCC) is one of the leading causes 
of cancer mortality in the world, with a limited number of cur-
rently available therapeutic options. Recent advances in research 
have suggested various molecular classifications for HCC, for ex-
ample the “hepatoblast signature,” “cholangiocarcinoma-like sig-
nature,” “epithelial cellular adhesion molecule (EpCAM)–posi-
tive signature,” and “5-gene score,” which help to identify subsets 
of HCC with poor prognosis and aggressive biological behavior, 
and which also point to the heterogeneity of HCC.1-4 Translat-
ing the molecular classifications into surgical pathology practice 
would potentially add more functionally and clinically relevant 
information in addition to the purely morphological diagnosis, 
and such endeavors have resulted in new classifications of vari-
ous cancers, including HCC, which reflect the histopathologi-
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cal, immunophenotypical and molecular features of the tumors. 
Interestingly, a remarkable number of the proposed poor 
prognostic signatures for HCC are related to “stemness,” and the 
expression of hepatic stem/progenitor cell–related markers in 
HCCs have been associated with an aggressive clinical behavior, 
compared to conventional HCCs that do not express these mark-
ers.5,6 It may be speculated that HCCs with “stemness”-related 
marker expression result from the malignant transformation of 
hepatic stem/progenitor cells, or from the dedifferentiation of 
conventional HCCs that acquire “stemness”-related markers dur-
ing tumor progression. Whatever the pathogenesis, these tu-
mors show features of aggressive behavior, such as frequent vas-
cular invasion, and poor prognosis, up-regulation of epithelial-
mesenchymal transition-related genes, longer telomeres and 
increased resistance to chemotherapeutic agents.5,7,8 
It is still uncertain which marker is the best one for identify-
ing this aggressive subgroup of HCCs; most of the recent litera-
ture has focused on K19, EpCAM, and CD133. Recent studies 
have proposed as a novel marker for the progenitor subclass of 
HCC Sal-like protein 4 (SALL4), which is known to be an im-
portant regulator of pluripotency in embryonic stem cells.9-12 In 
this study, we investigated the usefulness of SALL4 as a prognos-
tic marker and a marker of “stemness” in HCC.
MATERIALS AND METHODS
Case selection and review
This study was approved by the Institutional Review Board of 
Seoul National University Bundang Hospital (B-1502-286-302). 
One hundred and ninety consecutive cases of surgically resected 
or explanted HCCs were enrolled in this study, and were re-
trieved from the surgical pathology files of Seoul National Uni-
versity Bundang Hospital from May 2003 to April 2010. The 
clinicopathological characteristics of the cases are summarized 
in Table 1. The electronic medical records, surgical pathology 
reports, and the hematoxylin and eosin-stained slides were re-
viewed for each case, and the clinicopathological variables noted 
included tumor size, multiplicity (including intrahepatic me-
tastasis/satellite nodules and multicentric occurrences), histo-
logical differentiation according to the Edmondson-Steiner grade 
(the highest grade in tumors with heterogeneity), the presence 
of microvascular or major vascular invasion, the patient demo-
graphics (age and sex), and the presence of an underlying etiol-
ogy (e.g., hepatitis B, C, alcohol). Follow-up data was also ob-
tained from the medical records, including recurrences (including 
local recurrence and distant metastasis) and death. The median 
follow-up period was 52 months (range, 0 to 133 months). Over-
all survival was defined as the interval from initial surgical treat-
ment for HCC to the date of death, and disease-free survival as 
the interval from initial treatment to local or distant recurrence. 
Tissue microarray construction and immunohistochemistry
Tissue cores measuring 2 mm in diameter were sampled from 
formalin-fixed paraffin-embedded HCC tissues and arranged in 
recipient tissue array blocks using a trephine apparatus (Super-
biochips Laboratories, Seoul, Korea). Two or three cores were 
sampled from each HCC, depending on the amount of histolog-
ical heterogeneity present in the tumor. One core was sampled 
from the corresponding non-neoplastic liver for each case. Four 
μm-thick sections were obtained from the tissue microarray 
blocks and subjected to immunohistochemical staining for SALL4 
Table 1. Clinicopathologic characteristics of the HCC patients (n = 
190)
Characteristic No. (%)
Age (yr) 58.1 ± 11.8
Sex 
Male 151 (79.5)
Female 39 (20.1)
Etiology 
Hepatitis B 136 (71.6)
Hepatitis C 17 (8.9)
Alcohol 8 (4.2)
Others 30 (15.8)
Serum alpha-fetoprotein (IU/mL) 1,634.6 ± 4,590.4
Serum PIVKA-II (AU/mL) 661.2 ± 1,528.9
Multiplicity
Absent 106 (55.8)
Present 31 (16.3)
Tumor size (cm)a 4.6 ± 3.0
Edmondson-Steiner grade
I 1 (0.5)
II 47 (24.7)
III 122 (64.2)
IV 20 (10.5)
Microvascular invasion 
Absent 116 (61.1)
Present 74 (38.9)
Major vessel invasionb 
Absent 168 (88.4)
Present 22 (11.6)
Follow-up
Recurrencec 102 (53.7)
Deaths due to HCC 24 (12.6)
Values are presented as mean ± standard deviation or number (%).
HCC, hepatocellular carcinomas.
aSize of largest tumor in case of multiple tumors; bMain or first order branch-
es of portal vein and/or one or more of right, middle or left hepatic veins; cLo-
cal recurrence or distant metastasis.
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(1:100, mouse monoclonal antibody, clone EE-30, Santa Cruz 
Technologies Inc., Santa Cruz, CA, USA), K19 (1:150, mouse 
monoclonal antibody, clone BA17, Dako, Glostrup, Denmark) 
and EpCAM (1:3,000, mouse monoclonal antibody, clone VU-
1D9, Calbiochem, Darmstadt, Germany). Briefly, tissue sec-
tions were deparaffinized in xylene, rehydrated in graded alco-
hol, and antigen retrieval was performed using citrate buffer 
(pH 6.0) for 15 minutes. Sections were incubated with the pri-
mary antibodies at room temperature for 30 minutes, and then 
incubated with secondary antibodies (EnVision Detection Sys-
tem, Dako). Counterstaining was performed using Mayer’s he-
matoxylin and the stained slides were mounted. 
SALL4 was expressed in the tumor cell nuclei, and positivity 
for SALL4 expression was defined as nuclear staining for the 
A
C
E
B
D
F
Fig. 1. Immunohistochemical stain results. Nuclear SALL4 staining is seen in a case of HCC (A), which is weaker and clumped (inset) com-
pared to the strong nuclear staining seen in testicular seminoma (B). Clumped nuclear SALL4 expression is seen in another case of HCC 
with fibrous stroma (C). The non-neoplastic liver is negative for SALL4, except for occasional faintly positive cells in the ductular reactions (D, 
arrows). Nuclear SALL4 staining (E) is seen in an HCC with EpCAM expression (F). SALL4, Sal-like protein 4; HCC, hepatocellular carcino-
ma; EpCAM, epithelial cellular adhesion molecule.
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protein in more than 10% of the tumor cells after calculating 
the SALL4-labeling index (a ratio of positive nuclei/total nuclei 
under the 400 × field magnification) with the help of the Image 
J software (downloaded from http://imagej.nih.gov/ij). A testic-
ular seminoma tissue sample was used as a positive control for 
SALL4. Membranous and/or cytoplasmic staining in the tumor 
cells were counted as positive for EpCAM and K19. 
Statistical analysis
All statistical analyses were conducted using IBM SPSS ver. 
21 (IBM Corp., Armonk, NY, USA). Chi-square, Fisher’s exact 
and t tests were performed as deemed appropriate. Univariable 
analyses for overall survival and disease-free survival were per-
formed using the Kaplan-Meier method and log-rank tests. Sta-
tistically significant variables from the univariable analysis were 
entered into the multivariable analyses using the Cox proportion-
al hazard method. Statistical significance was defined as p < .05.
RESULTS
SALL4, K19, and EpCAM expression in HCC
The immunohistochemical stain results and the expression 
frequencies of SALL4, K19, and EpCAM are summarized in 
Figs. 1 and 2, respectively. The SALL4 nuclear labeling index 
ranged from 0% to 78.9% (mean ± standard deviation, 8.9 ± 
19.2%) in the 190 HCCs, and 39 cases (20.5%) were deemed 
positive for SALL4 expression (labeling index ≥ 10%). Although 
a definite nuclear staining was present in the tumor cells, the in-
tensity of staining was generally not as strong as in the positive 
control tissue (testicular seminoma) (Fig. 1A–C). In some areas, 
the nuclear staining was punctate and only identifiable at higher 
power magnification. SALL4 positivity was generally uniformly 
distributed in the HCCs without predilections for a particular 
morphological tumor cell: some SALL4-positive tumor cells 
were small with increased nuclear/cytoplasmic ratios reminiscent 
of the stem/progenitor cell phenotype, while others were more 
typical HCCs with various degrees of differentiation. In the ad-
jacent non-neoplastic liver, the hepatocytes and bile ducts did 
not stain for SALL4, and interestingly, SALL4 positivity was seen 
in occasional ductular reactions, although the staining was very 
faint and barely visible (Fig. 1D).
K19 and EpCAM expression data were available for 189 cases 
(due to tissue core loss in 1 case). K19 and EpCAM were ex-
pressed in 30 (15.9%) and 92 (48.7%) cases, respectively, in the 
typical membranous/cytoplasmic pattern, and they were also 
expressed in the bile ducts and ductular reactions in the non-
neoplastic livers. A significant positive correlation was seen be-
tween EpCAM and K19 expression: K19 positivity was seen in 
27 out of 92 EpCAM-positive HCCs (29.3%) compared to 3 
out of 97 EpCAM negative HCCs (3.1%) (p < .001). SALL4 ex-
pression was more frequently seen in EpCAM-positive HCCs 
(26/92, 28.3%) compared to EpCAM-negative HCCs (13/97, 
13.4%) (p = .013) (Fig. 1E, F). However, there was no significant 
correlation between SALL4 and K19 expression: only 3.2% of 
the HCCs demonstrated positivity for both SALL4 and K19 
(Fig. 2). The relationships between the expression of SALL4, K19, 
and EpCAM in HCCs are summarized in a Venn diagram in 
Fig. 2. 
Correlation with clinicopathological variables and survival
Univariable analysis demonstrated that SALL4 expression was 
significantly associated with reduced overall survival (p = .014) 
(Fig. 3A). In addition to SALL4 expression, larger tumor size (> 
3 cm, p = .045), multiplicity of tumor (p = .001), major vascular 
invasion (p = .046) and higher T stage (stage 3 or 4, p < .001) 
were significantly associated with decreased overall survival. In 
comparison, SALL4 expression was not significantly associated 
with disease-free survival (Fig. 3B), while larger size (> 3 cm, p = 
.009), multiplicity (p = .002) and higher T stage (stage 3 or 4, p = 
.019) were significantly associated with reduced disease-free 
survival. HCCs with K19 expression had a tendency for de-
creased overall survival, although this result was not statistically 
significant (p = .063), while disease-free survival was significantly 
decreased for K19 expressing HCCs (p = .001) (Fig. 3C, D). Ep-
CAM expression was associated with a tendency for decreased 
EpCAM
n = 92 (48.7%)
SALL4
n = 39 (20.6%)a
K19
n = 30 (15.9%)
3 (1.6%)
6 (3.2%)
13
(6.9%)
20
(10.6%)
45
(23.8%)
21
(11.1%)
Fig. 2. Venn diagram summarizing the relationships between the 
expression of SALL4 (pink), K19 (blue), and EpCAM (green) in 
HCCs. While SALL4 expression is frequently co-expressed with 
EpCAM (26/39, 66.7%), K19 expression was only seen in 6 of 
SALL4-positive HCCs (15.4%). SALL4, Sal-like protein 4; EpCAM, 
epithelial cellular adhesion molecule; HCC, hepatocellular carcino-
ma. aTotal n = 189 with SALL4, EpCAM, and K19 data.
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overall survival (p = .053); however, it was not associated with 
disease-free survival. 
Interestingly, when we performed the survival analysis after 
combining EpCAM and SALL4 expression status, HCCs that 
expressed both SALL4 and EpCAM were associated with signifi-
cantly decreased overall survival, compared to those cases which 
were negative for both these markers (p = .031) (Fig. 4). In addi-
tion, while EpCAM-negative HCCs were associated with a rela-
tively favorable outcome compared to EpCAM-positive HCCs 
during the earlier follow-up period (< 5 years), EpCAM-negative 
HCCs with SALL4-positivity showed an abrupt decrease in over-
all survival after 5 years of follow-up.
On multivariable analysis, SALL4 (p = .004), multiplicity (p = 
.016) and higher T stage (p = .004) remained as significant in-
dependent predictors of decreased overall survival (Table 2). For 
disease-free survival, larger tumor size (> 3 cm, p = .019), and mul-
tiplicity (p = .004) were independent prognostic factors. 
SALL4 expression was not significantly associated with other 
clinicopathological parameters of tumor aggressiveness, such as 
presence of vascular invasion, larger tumors, and multiplicity 
(Table 3). On the other hand, EpCAM expression in HCCs was 
more frequently associated with poor histological differentiation 
Fig. 3. Kaplan-Meier survival curves demonstrating decreased overall survival (A) and disease-free survival (B) in HCCs with SALL4 expres-
sion, and decreased overall survival (C) and disease-free survival (D) in HCCs with K19 expression. HCC, hepatocellular carcinoma; SALL4, 
Sal-like protein 4.
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(p = .019), microvascular invasion (p = .011), younger age (p = 
.020), B-viral etiology (p = .010), and high serum α-fetoprotein 
(AFP) levels (p = .023), and K19 expression was more frequently 
associated with higher serum AFP levels (p = .032), major vas-
cular invasion (p = .010), and higher pathological T stage (3 or 4, 
p = .011). Increased tumor size was also more frequent in K19-
positive HCCs, although not statistically significant (p = .076).
DISCUSSION
HCCs with “stemness”-related marker expression—those that 
have the histomorphological features of conventional HCCs but 
express markers related to stemness on immunohistochemis-
try—have been receiving increasing interest over the past sev-
eral years, as there is accumulating evidence that they are asso-
ciated with aggressive behavior and poor prognosis, compared 
to conventional HCCs that do not express these markers.5,6 The 
more frequently discussed markers of stemness in HCCs in-
clude K19, EpCAM, and CD133; however, it is still uncertain 
which marker best represents stemness in HCCs, and there is 
still a growing number of putative markers of stemness in the lit-
erature, including the recently proposed SALL4, which need 
further validation.10 We were interested to see whether SALL4 
expression in HCCs is indeed associated with the expression of 
other more established markers of stemness (K19 and EpCAM) 
and whether it has clinicopathological implications in our co-
hort of resected HCCs. Interestingly, we found SALL4 expression 
in 20.5% of HCCs, that SALL4 expression is positively corre-
lated with EpCAM expression, and also that it has prognostic 
implications. 
SALL4 is a zinc finger transcriptional activator located on 
chromosome 20q13.13-13.2 that is required for the mainte-
nance of pluripotent embryonic stem cells, potentially through 
interactions with Oct3/4, Sox2, and Nanog.12-14 Mutation in 
SALL4 results in the Okihiro syndrome, a rare autosomal dom-
inant disorder characterized by multiple organ defects.14 SALL4 
has been found to be expressed in leukemias and hematopoietic 
stem cells, and also in solid tumors such as germ cell tumors and 
AFP-producing gastric cancers, suggesting that SALL4 may be 
a marker of embryonic stem cells and also cancer stem cells.15-18 
In the fetal murine liver, SALL4 has been shown to be expressed 
in hepatic stem/progenitor cells, but the expression diminishes 
gradually during development and is not seen in adult hepato-
cytes.19 These findings suggest that SALL4 may be a good mark-
er of hepatic stem/progenitor cells and HCC cancer stem cells. 
Over the past two years, there has been increasing interest in 
SALL4 as a potential marker for identifying HCCs with features 
of “stemness,” aggressive behavior, and poor prognosis. Oikawa 
et al.9 demonstrated a decreased overall survival in their profil-
ing analysis of 110 HCCs (from the microarray dataset pub-
lished by Lee et al.1), and also showed that the overexpression of 
SALL4 in liver cancer cells induced the expression of K19 and 
Table 2. Multivariable analysis results: independent predictors of decreased overall survival and disease-free survival
p-value Hazard ratio
95% Confidence interval
Lower Upper
Overall survival
SALL4 positivity .004 3.556 1.511 8.367
Multiplicity of tumor .016 2.929 1.223 7.014
High T stage (T3 and 4) .004 3.583 1.486 8.636
Disease-free survival
Size (> 3 cm) .019 1.703 1.092 2.656
Multiplicity of tumor .004 1.937 1.234 3.039
SALL4, Sal-like protein 4.
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Fig. 4. Kaplan-Meier survival curves demonstrating the differences 
in overall survival in HCCs after combining EpCAM and SALL4 ex-
pression status. HCC, hepatocellular carcinoma; EpCAM, epithelial 
cellular adhesion molecule; SALL4, Sal-like protein 4.
Overall survival (mo)
EpCAM- SALL4-
EpCAM+ SALL4-
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http://jpatholtm.org/http://dx.doi.org/10.4132/jptm.2015.07.09
SALL4 Expression in Hepatocellular Carcinoma  •     379
EpCAM, suggesting that SALL4 may be a marker of stem cells. 
Zeng et al.11 demonstrated a decreased recurrence-free survival 
in SALL4-positive HCCs, and SALL4 activation in cell lines re-
sulted in the up-regulation of hepatic stem cell markers KRT19, 
EPCAM, and CD44. Another extensive study showed a poor 
overall survival in SALL4-positive HCCs in two independent 
cohorts (Singapore, n = 179; Hong Kong, n = 228), in addition 
to an enrichment of progenitor-like gene signatures and overex-
pression of proliferative and metastatic genes on gene expres-
sion analysis.10 In another recent analysis of Western HCCs, 
higher tumor grade, more frequent lymphovascular invasion 
and shorter recurrence-free and overall survivals were seen in 
SALL4-positive HCCs, although the SALL4-positivity was only 
seen very rarely (1.3%), suggesting differences in SALL4 expres-
sion status according to the etiology of HCC.20 The expression 
frequency of SALL4 in HCC has in fact varied widely in differ-
ent reports, ranging from 1.3% to 85%.9-11,20,21 It is plausible 
that a higher prevalence of hepatitis B virus infection may ac-
count for the higher frequency of SALL4-positivity in Eastern 
HCCs; interestingly, SALL4-positivity has been shown to be 
more frequently associated with hepatitis B virus infection.11 In 
addition, the differences in the antibodies, immunohistochemis-
try protocols, and the interpretation methods for defining “SALL4-
positivity” are also likely to account for the wide range of SALL4-
positivity reported in the literature. 
As it has been previously demonstrated that nuclear labeling 
for SALL4 in liver tissues is seen with high pH antigen retrieval 
and not as clearly with the conventional citrate buffer,9 we also 
Table 3. Clinicopathologic characteristics and immunohistochemical stain results of 190 HCCs
SALL4 
p-value
K19a 
p-value
EpCAMa 
p-value
Negative Positive Negative Positive Negative Positive
Frequency 151 (79.5) 39 (20.5) 159 (84.1) 30 (15.9) 97 (51.3) 92 (48.7)
Age (yr) .858 .694 .020
< 60 81 (53.6) 20 (51.3) 83 (52.2) 17 (56.7) 43 (44.3) 57 (62.0)
≥ 60 70 (46.4) 19 (48.7) 76 (47.8) 13 (43.3) 54 (55.7) 35 (38.0)
Sex 1.000 .808 .113
Male 32 (21.2) 8 (20.5) 33 (20.8) 7 (23.3) 16 (16.5) 24 (26.1)
Female 119 (78.8) 31 (79.5) 126 (79.2) 23 (76.7) 81 (83.5) 68 (73.9)
Etiology .319 .829 .010
Hepatitis B virus–related 40 (26.5) 14 (35.9) 45 (29.3) 9 (30.0) 36 (37.1) 18 (19.6)
Non-hepatitis B virus–related 111 (73.5) 25 (64.1) 114 (71.7) 8 (70.0) 61 (62.9) 74 (80.3)
Serum α-fetoprotein (IU/mL) (n = 132) 1.000 .032 .023
< 1,000 76 (76) 25 (78.1) 86 (80.4) 14 (58.3) 54 (85.7) 46 (79.3)
≥ 1,000 24 (24) 7 (21.9) 21 (19.6) 10 (41.7) 9 (14.3) 22 (20.7)
Multiplicity .825 .328 .372
Absent 120 (79.5) 32 (82.1) 129 (81.1) 22 (73.3) 80 (82.5) 71 (77.2)
Present 31 (20.5) 7 (17.9) 30 (18.9) 8 (26.7) 17 (17.5) 21 (22.8)
Tumor size (cm)b .432 .076 .873
< 5 105 (69.5) 30 (76.9) 118 (74.2) 17 (56.7) 70 (72.2) 65 (70.7)
≥ 5 16 (30.5) 9 (23.1) 41 (25.8) 13 (43.3) 27 (27.8) 27 (29.3)
Pathologic T stage 1.000 .011 .266
pT1/pT2 122 (80.8) 32 (82.1) 134 (84.3) 19 (63.3) 82 (84.5) 71 (77.2)
pT3a/pT3b/pT4 29 (19.2) 7 (17.9) 25 (15.7) 11 (36.7) 15 (15.5) 21 (22.8)
Edmondson-Steiner grade .410 .648 .019
I/II 36 (23.8) 12 (30.8) 42 (26.4) 6 (20.0) 32 (33) 16 (17.4)
III/IV 115 (76.2) 27 (69.2) 117 (73.6) 24 (80.0) 65 (67) 76 (82.6)
Microvascular invasion .581 .685 .011
Absent 94 (62.3) 22 (56.4) 98 (61.6) 17 (56.7) 68 (70.1) 47 (51.1)
Present 57 (37.7) 17 (43.6) 61 (38.4) 13 (43.3) 29 (29.9) 45 (48.9)
Major vessel invasionc .781 .010 .366
Absent 134 (88.7) 34 (87.2) 145 (91.2) 22 (73.3) 88 (90.7) 79 (85.9)
Present 17 (11.3) 5 (12.8) 14 (8.8) 8 (26.7) 9 (9.3) 13 (14.1)
Values are presented as number (%).
HCC, hepatocellular carcinomas; SALL4, Sal-like protein 4; EpCAM, epithelial cellular adhesion molecule. 
an = 189 (tissue core loss in 1 case); bSize of largest tumor in case of multiple tumors; cMain or first order branches of portal vein and/or one or more of right, 
middle or left hepatic veins.
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stained the same tissue microarrays for SALL4 using a different 
antigen retrieval method (Tris-EDTA buffer; pH 9.0) to see if 
there were differences in the staining pattern or frequency; how-
ever, the results were identical (data not shown). Therefore, 
SALL4 immunostaining is feasible using the citrate buffer (pH 
6.0) for antigen retrieval. We found that the nuclear staining for 
SALL4 in the testicular seminoma was very intense, diffuse and 
finely granular, in comparison to most SALL4-positive HCCs in 
which the nuclear staining was weaker and punctate or clumped, 
similar to a previous report.21 In practice, when faced with the oc-
casional diagnostic challenge of discriminating between HCC 
and yolk sac tumor—which may have similar morphological fea-
tures and also positivity for AFP and glypican-3—SALL4 im-
munohistochemistry may play a role, as the strong and diffuse 
staining for SALL4 is rarely seen in HCCs.21 However, as for the 
utility of SALL4 in HCCs as a prognostic marker and a marker of 
“stemness,” further validation in independent cohorts of HCC 
would be necessary, as the staining is not as intense, and there is 
likely to be interobserver variation in the interpretation of SALL4 
positivity. Although we found a significantly decreased overall 
survival and a higher frequency of EpCAM positivity in SALL4-
positive HCCs compared to SALL4-negative HCCs, we per-
formed a semi-manual count of the SALL4-labeling index with 
the help of an image analysis software, which is not always a fea-
sible method in routine pathology practice in comparison to the 
distinct cytoplasmic staining for K19 or EpCAM. 
Our finding of a positive correlation between SALL4 and Ep-
CAM expression in HCCs, poor overall survival in SALL4-posi-
tive HCCs, and positive (albeit weak and sporadic) staining in 
the ductular reactions support the recent literature that SALL4 
may be a useful marker of “stemness” in hepatic stem/progeni-
tor cells and HCCs. However, in contrast to K19 or EpCAM, the 
nuclear staining is not as easily appreciable by immunohisto-
chemistry, and other than being a prognostic indicator of poor 
overall survival, there were no significant correlations between 
SALL4 positivity and the clinicopathological parameters sug-
gestive of aggressiveness. Therefore, while SALL4 is an indepen-
dent prognostic factor for decreased overall survival in HCC pa-
tients and may be a potential marker for identifying the aggressive 
subgroup of HCCs with “stemness” features, further validation 
in larger HCC cohorts is required prior to further consideration 
of SALL4 as a good marker of “stemness” in liver specimens. 
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